Skip to main content
. 2020 Feb 21;2(1):dlaa002. doi: 10.1093/jacamr/dlaa002

Table 2.

In vivo assessment of potential resistance to rifampicin, minocycline and/or chlorohexidine

Citation Drug Device: how is drug attached; concentration Animal model species (n); implant site; duration Organism(s) assessed Methodology; resistance measurement Results After contact with the device, which of the following does the study show: (i) no change in resistance; or (ii) development of new resistance
Rifampicin (n = 3)
 Avramovic et al., 199136 R vascular graft; soaked in 100 mg aqueous R sheep (20); carotid artery; 3 weeks SA Breakthrough ZOI; R antibiotic disc All SA isolated from R-treated grafts remained sensitive no change in resistance
 Garrison et al., 199718 R uncoated vascular graft; aqueous 4× and 1000× MIC R infused in subcutaneous pocket mouse (42); subcutaneous pocket; 4, 18 and 42 h SE Biofilm eradication; MIC broth dilution MIC of recovered SE from high-dose R increased from BL (0.1 to >30 mg/L) development of new resistance
 Sardelic et al., 199537 R vascular graft; soaked in 1.2 mg/mL aqueous R sheep (9); carotid artery; 3 weeks MRSA Breakthrough MIC; agar dilution Breakthrough MRSA had same R MIC as starting inoculum no change in resistance

ZOI, zone of inhibition; BL, baseline.